Divalproex Sodium: Depakote, Epival, Valcote

CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.

{m} Entries

Phase
Study Indication or Disease
Study Name
M02-547 AbbVie_IU_icons_outlined_v3 Schizophrenia CSR.ORG A Randomized, Double-Blind Study of the Safety and Efficacy of Depakote ER plus an Atypical Antipsychotic vs. an Atypical Antips…
M03-647 AbbVie_IU_icons_outlined_v3 Bipolar Disorder CSR.ORG An Open-Label Study to Evaluate the Safety of Depakote® ER in the Treatment of Mania Associated with Bipolar I Disorder in Child…
M03-648 AbbVie_IU_icons_outlined_v3 Migraine CSR.ORG Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents: An Open-Label, Long-Term Safety Study Abb…
M02-461 AbbVie_IU_icons_outlined_v3 Epilepsy (Seizures) CSR.ORG A 14-Day, Randomized, Open-Label, Cross-Over, Single Center Outpatient Study of Depakote Delayed-Release or Depakote Sprinkle vs…
M02-555 AbbVie_IU_icons_outlined_v3 Bipolar Disorder CSR.ORG An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated…
M02-554 AbbVie_IU_icons_outlined_v3 Migraine CSR.ORG The Safety of Divalproex Sodium Extended Release Tablets in Migraine Prophylaxis: An Open-Label Extension Study in Adolescents…
M01-342 AbbVie_IU_icons_outlined_v3 Bipolar Disorder CSR.ORG A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Mania Associat...
M04-714 AbbVie_IU_icons_outlined_v3 Partial Seizures CSR.ORG An Open-Label Multicenter Study of the Long-Term Safety of Depakote® Sprinkle Capsules in the Treatment of Partial Seizures in C…
M02-488 AbbVie_IU_icons_outlined_v3 Migraine Phase 3 The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Double-Blind, Placebo-Controlle..
M02-540 AbbVie_IU_icons_outlined_v3 Bipolar Disorder CSR.ORG A 21-Day, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Depakote ER in the Treatment…
M02-551 AbbVie_IU_icons_outlined_v3 Depression-Bipolar Phase 4 A Randomized, Double-Blind Study of Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects during the Maintenance Phase Of Bipolar Illness